UBS Group
NAUT icon

UBS Group’s Nautilus Biotechnolgy NAUT Stock Holding History

UBS Group’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32K Sell
17,110
-9,793
-36% -$25.9K ﹤0.01% 7852
2026
Q1 		$104K Buy
26,903
+21,740
+421% +$53.4K ﹤0.01% 6981
2025
Q4 		$10.1K Buy
5,163
+4,693
+999% +$7.7K ﹤0.01% 8244
2025
Q3 		$397 Sell
470
-15,850
-97% -$11.6K ﹤0.01% 9694
2025
Q2 		$11.8K Sell
16,320
-5,450
-25% -$4.09K ﹤0.01% 8766
2025
Q1 		$18.7K Sell
21,770
-25,460
-54% -$37.8K ﹤0.01% 8279
2024
Q4 		$79.3K Buy
47,230
+19,449
+70% +$46.5K ﹤0.01% 7013
2024
Q3 		$79.2K Buy
27,781
+7,628
+38% +$19.7K ﹤0.01% 6517
2024
Q2 		$47.2K Sell
20,153
-31,434
-61% -$82.1K ﹤0.01% 6733
2024
Q1 		$152K Sell
51,587
-5,143
-9% -$14.6K ﹤0.01% 6029
2023
Q4 		$170K Buy
56,730
+28,999
+105% +$83K ﹤0.01% 5877
2023
Q3 		$87.6K Sell
27,731
-2,833
-9% -$9.22K ﹤0.01% 5916
2023
Q2 		$118K Buy
30,564
+13,251
+77% +$38.2K ﹤0.01% 5868
2023
Q1 		$48K Buy
17,313
+2,864
+20% +$6.01K ﹤0.01% 6491
2022
Q4 		$26K Buy
+14,449
New +$27.9K ﹤0.01% 7387
2022
Q2 		– Sell
-804
Closed -$3K – 10704
2022
Q1 		$3K Sell
804
-4,827
-86% -$19.8K ﹤0.01% 9464
2021
Q4 		$30K Sell
5,631
-31,682
-85% -$170K ﹤0.01% 7403
2021
Q3 		$229K Buy
+37,313
New +$297K ﹤0.01% 5216
2020
Q4 		– Sell
-147
Closed -$2K – 8617
2020
Q3 		$2K Buy
+147
New +$1.57K ﹤0.01% 7676

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

UBS Group's NAUT Position: Q2 2026 in Review

UBS Group reduced its Nautilus Biotechnolgy (NAUT) stake by 36% in Q2 2026, selling an estimated $25.9K and leaving 17,110 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #7852.

UBS Group first reported a position in NAUT in Q3 2020 and has held it in 19 quarters since. The position peaked at $229K in Q3 2021. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • UBS Group held 17,110 shares of Nautilus Biotechnolgy worth $32K as of Q2 2026.
  • UBS Group sold 9,793 Nautilus Biotechnolgy shares in Q2 2026, an estimated $25.9K.
  • Nautilus Biotechnolgy made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7852 holding.
  • UBS Group first reported a position in Nautilus Biotechnolgy in Q3 2020 and has held it in 19 quarters since.
  • UBS Group's Nautilus Biotechnolgy position peaked at $229K in Q3 2021.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.